To reach our communications team for Europe, please email: press@daiichi-sankyo.eu To reach our communications team in Tokyo, please visit: https://www.daiichisankyo.com/media/ To reach Investor Relations, please email: DaiichiSankyoIR@daiichisankyo.co.jpAbout...
Investor Relations Contact: DaiichiSankyoIR_jp@daiichisankyo.com Source:Daiichi Sankyo Company, Ltd
Daiichi Sankyo Co., Ltd. kawase.masashi.a2@daiichisankyo.co.jp +81 3 6225 1126 (office) EU: Lydia Worms Daiichi Sankyo Europe GmbH lydia.worms@daiichi-sankyo.eu +49 (89) 7808751 (office) +49 176 11780861 (mobile) Investor Relations Contact: DaiichiSankyoIR@daiichisankyo.co.jp Back to pr...
TOKYO, MUNICH &BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited(hereafter,Daiichi Sankyo) announced today that it has entered into a global development and commercialization agreement withAstraZeneca(LSE, STO, NYSE: AZN) for Daiichi Sankyo’s DS-1062, a TROP2 ...
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global Head of Research & Development as of April 1, 2021.
Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates...
Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
Investor Relations Contact: DaiichiSankyoIR@daiichisankyo.co.jp LYSA-LYSARC-CALYM Amel Bourakaz Head of Communication LYSA � LYSARC � CALYM amel.bouakaz@lysarc.org Direct : +33 (0)4 27 01 27 31 Mobile : +33 (0)6 76 93 86 61...
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO